• Innoviva subsidiary Innoviva Specialty Therapeutics will present four abstracts at IDWeek 2026, running October 21-24 in Washington, D.C.
• Three ceftobiprole (Zevtera) posters cover activity against contemporary U.S. clinical isolates and pediatric use, with presentations scheduled for October 22 and 24.
• An October 24 oral presentation examines zoliflodacin (Nuzolvence) eradication of urogenital gonorrhea in patients co-infected with chlamydia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190800BIZWIRE_USPR_____20261019_BW935081) on October 19, 2026, and is solely responsible for the information contained therein.